Molecular-based allergy diagnostics in the real world: evidence for a cost explosion and an impact vacuum by Niall Conlon et al.
ORAL PRESENTATION Open Access
Molecular-based allergy diagnostics in the real
world: evidence for a cost explosion and an
impact vacuum
Niall Conlon1,2*, Lisa Devlin2, Cathal Steele2, Hiba Shendi2, Matthew Doré2, John Thompson2, Alison Donnelly2,
J. David M. Edgar2
From Food Allergy and Anaphylaxis Meeting 2014
Dublin, Ireland. 9-11 October 2014
Background
Molecular-based allergy (MA) diagnostics are used to
identify patient sensitization to individual allergen com-
ponents. Despite a recent consensus statement, the clini-
cal utility of MA diagnostics in routine practice remains
unclear.
Aim
To review the cost and usage patterns of MA diagnos-
tics at a regional level and to estimate the clinical value
of such testing strategies.
Methods
Laboratory data on Northern Ireland MA diagnostics
ordering between 2010 and 2013 was obtained. Data
specific to Regional Immunology Service patients from
2013 was further interrogated. A retrospective review of
case records from adults (n=70) and children (n=53)
was carried out to determine the impact of MA test
results.
Results
MA testing has increased annually since its introduction
in 2010. Spending on MA diagnostics exceeded £20,000
in 2013. Increases in test numbers were observed across
a range of allergen groups during the time period and
suggests routine ordering (Figure 1). Analysis of request
sources indicated a surge in test numbers across 5 key
user hospital units (Figure 2). Additionally, a marked
increase in MA diagnostics orders from non-specialist
sources was noted.
Use of MA diagnostics introduced a mean increase in
cost of 156% in adults (range 11%-900%) and 197% in
children (range 9%-600%)(Table 1). Review of individual
cases indicated that MA diagnostics had no specific
impact on diagnosis or management in 78.6% of adults
and 83.0% of children.
Discussion
This study suggests that the use of MA diagnostics is
entering routine clinical practice and is associated with
a cost premium. The minimal clinical impact of these
testing modalities argues for the establishment of
demand management programs in resource-constrained
environments.
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Mean age (sd) 31.9 (12.3) 9.2 (4.2)
% cost increase with MA (range) 156 (11-900) 197 (9-600)
MA test results altered management,
n(%)
6 (8.6) 7 (13.2)
MA test results provided useful
diagnostic support, n(%)
9 (12.8) 2 (3.7)
MA test results had no impact on
diagnosis or management, n(%)
55 (78.6) 44 (83)
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